➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Dow
Express Scripts
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

VENLAFAXINE HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Venlafaxine Hydrochloride, and what generic alternatives are available?

Venlafaxine Hydrochloride is a drug marketed by Anchen Pharms, Annora Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Intellipharmaceutics, Inventia Hlthcare, Macleods Pharms Ltd, Mylan, Orchid Hlthcare, Teva, Torrent Pharms Llc, Valeant Pharms North, Wockhardt, Zydus Pharms Usa Inc, Cadila Pharms Ltd, Dexcel Pharma, Nostrum Labs Inc, Osmotica Pharm, Sun Pharm, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Fosun Pharma, Heritage Pharms Inc, Pliva Hrvatska Doo, Prinston Inc, Sun Pharm Inds Inc, Yaopharma Co Ltd, and Zydus Pharms Usa. and is included in thirty-three NDAs.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Venlafaxine Hydrochloride

A generic version of VENLAFAXINE HYDROCHLORIDE was approved as venlafaxine hydrochloride by TEVA on August 3rd, 2006.

  Start Trial

Drug patent expirations by year for VENLAFAXINE HYDROCHLORIDE
Recent Clinical Trials for VENLAFAXINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Online PsychoTherapy ClinicN/A
Queen's UniversityN/A
Medical University of South CarolinaPhase 2/Phase 3

See all VENLAFAXINE HYDROCHLORIDE clinical trials

Pharmacology for VENLAFAXINE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for VENLAFAXINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for VENLAFAXINE HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
VENLAFAXINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL venlafaxine hydrochloride 022104 2011-01-10
VENLAFAXINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL venlafaxine hydrochloride 022104 2009-02-12
EFFEXOR XR CAPSULE, EXTENDED RELEASE;ORAL venlafaxine hydrochloride 020699 2007-05-03
EFFEXOR TABLET;ORAL venlafaxine hydrochloride 020151 2005-11-03

US Patents and Regulatory Information for VENLAFAXINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET;ORAL 090555-005 Apr 7, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Pliva Hrvatska Doo VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET;ORAL 078517-004 Jun 13, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Zydus Pharms Usa Inc VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 090174-002 Apr 14, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Torrent Pharms Llc VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 090899-002 Jun 1, 2011 AB RX No No   Start Trial   Start Trial   Start Trial
Fosun Pharma VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET;ORAL 077515-004 Jun 13, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VENLAFAXINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-001 May 20, 2008   Start Trial   Start Trial
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-004 May 20, 2008   Start Trial   Start Trial
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-004 May 20, 2008   Start Trial   Start Trial
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-002 May 20, 2008   Start Trial   Start Trial
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-002 May 20, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Dow
Mallinckrodt
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.